Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Ph(+) ALL, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy. Treatment outcome with imatinib-based regimens has improved compared with hi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematology 2009, Vol.2009 (1), p.371-381
Hauptverfasser:	Ottmann, Oliver G, Pfeifer, Heike
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenal Cortex Hormones - administration & dosage Adult Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzamides Central Nervous System - pathology Child Combined Modality Therapy Dasatinib Drug Resistance, Neoplasm Fusion Proteins, bcr-abl - antagonists & inhibitors Fusion Proteins, bcr-abl - genetics Hematopoietic Stem Cell Transplantation Humans Imatinib Mesylate Leukemic Infiltration - drug therapy Leukemic Infiltration - prevention & control Mutation Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - genetics Neoplasm, Residual Philadelphia Chromosome Piperazines - administration & dosage Piperazines - therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Pyrimidines - administration & dosage Pyrimidines - therapeutic use Salvage Therapy Secondary Prevention Thiazoles - administration & dosage Thiazoles - therapeutic use Transplantation Conditioning - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!